{"filing":{"accession_number":"0001829126-26-007510","cik":"0002079364","ticker":null,"company_name":"Veraxa Biotech AG","form":"6-K","filing_date":"2026-07-10","report_date":null,"primary_document":"veraxabiotechag_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2079364/000182912626007510/veraxabiotechag_6k.htm"},"events":[{"id":17340,"run_id":15520,"accession_number":"0001829126-26-007510","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The press release announces the appointment of Carl von Halem as Interim Chief Financial Officer of VERAXA Biotech AG, succeeding Torsten Bürgermeister. While the disclosure also references Bürgermeister's departure, the principal disclosed action is the appointment of a named executive to a C-suite role. The appointment of a CFO is material to investors as it affects the company's financial leadership and operational continuity, particularly given the company's recent NASDAQ listing and growth phase.","company_name":"Veraxa Biotech AG","ticker":null,"filing_date":"2026-07-10","form":"6-K","submitted_at":null,"items":[{"id":15775,"accession_number":"0001829126-26-007510","item_number":"EX-99.1","item_title":"veraxabiotechag_ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The press release announces the appointment of Carl von Halem as Interim Chief Financial Officer of VERAXA Biotech AG, succeeding Torsten Bürgermeister. While the disclosure also references Bürgermeister's departure, the principal disclosed action is the appointment of a named executive to a C-suite role. The appointment of a CFO is material to investors as it affects the company's financial leadership and operational continuity, particularly given the company's recent NASDAQ listing and growth phase.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:03:36.949011+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15775,"accession_number":"0001829126-26-007510","item_number":"EX-99.1","item_title":"veraxabiotechag_ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The press release announces the appointment of Carl von Halem as Interim Chief Financial Officer of VERAXA Biotech AG, succeeding Torsten Bürgermeister. While the disclosure also references Bürgermeister's departure, the principal disclosed action is the appointment of a named executive to a C-suite role. The appointment of a CFO is material to investors as it affects the company's financial leadership and operational continuity, particularly given the company's recent NASDAQ listing and growth phase.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:03:36.949011+00:00","company_name":"Veraxa Biotech AG","ticker":null,"filing_date":"2026-07-10"}]}